

Vitiligo PSP completed in 2010													
Indicative Uncertainty		Why is there uncertainty?	What is person's age?	Which types of treatments? 1	Which types of treatments? 2	Which types of treatments? 3	Source	Original uncertainty	References to reliable up-to-date systematic reviews	Systematic reviews in preparation	Systematic reviews that need updating or extending	Ongoing controlled trials	Which outcomes?
Are calcineurin inhibitors (tacrolimus or pimecrolimus) effective in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082393	Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Are calcineurin inhibitors (tacrolimus or pimecrolimus) more effective if used to treat vitiligo when it first appears, rather than waiting until the disease has spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Are calcineurin inhibitors (tacrolimus or pimecrolimus) more effective in treating vitiligo when combined with steroid creams?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Are creams and ointments (e.g. steroid creams) more effective when combined with natural sunlight?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental	Drug		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Are moisturisers effective in stopping the spread of vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Are steroid creams more effective if used to treat vitiligo when it first appears, rather than waiting until the disease has spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

Are there any long term side effects associated with steroid cream treatments?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Side effects/Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082393
Are there any risks associated with depigmentation in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Unclassified			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Risks, safety and side effects
Are there any side effects associated with permanent, or semi-permanent, cosmetic camouflage for the management of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Unclassified			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Side effects
Are there any side effects associated with using calcineurin inhibitors (tacrolimus or pimecrolimus) to treat vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082394	Side effects
Are there any side effects associated with using piperine (black pepper) cream to treat vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Side effects
Are there any side effects associated with using pseudocatalase cream combined with UVB light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Side effects
Are there any side effects associated with using steroid creams in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082393	Side effects
Are there any side effects associated with using UVA light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Side effects
Are there any side effects associated with UVB light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Side effects
Are Vitamin D analogues (calcipotriol and tacalcitol) more effective in treating vitiligo when combined with light therapy?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

Are Vitamin D analogues (calcipotriol and tacalcitol) more effective in treating vitiligo when combined with steroid creams?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Does the addition of psychological interventions (e.g. counselling, support) to patients receiving cosmetic camouflage improve their quality of life?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Psychological therapy			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 9 Vitiligo Ranked 9; Patient rank 6, HP 6	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Does treatment with immunosuppressants help patients with vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 1 Vitiligo Ranked 1; Patient rank 3rd, Health Professional 0	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How does natural sunlight interact with other treatments for vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Environmental		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				repigmentation
How effective are anti-oxidants when combined with mitochondrial stimulating cream in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are anti-oxidants when combined with tablets such as phenylalanine in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are herbal remedies in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Complementary therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

How effective are hormones or hormone related substances that stimulate pigment cells (MSH analogues, afamelanotide) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 6 Vitiligo Ranked 6; Patient rank 8, HP 16	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are other complementary therapies (e.g. aloevera, UNANI) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Complementary therapies		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo NCT01006421	Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are SAD light boxes in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are steroid creams in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis). NCT01082393	Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are steroid tablets in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is cosmetic camouflage for the management of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

How effective is cream containing Vitamin D analogues (calcipotriol and tacalcitol) in the treatment of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is education into the use of cosmetic camouflage for the management of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Unclassified			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is hormone replacement therapy (HRT) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is laser therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is laser therapy when combined with creams or ointments (e.g. steroid cream) in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is levamisole in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

How effective is levamisole taken by mouth when combined with creams or ointments (e.g. steroid cream) in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is melagenina in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Complementary therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is micropigmentation in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Surgery			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is natural sunlight in achieving repigmentation of the skin in patients with vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is nerve stimulation in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is piperine (black pepper) cream in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 11	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

How effective is piperine taken by mouth in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is plant-based catalase/dismutase in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is psoralen cream/ointment combined with exposure to natural sunlight (topical PUVAso) in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is PUVA therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is PUVA therapy when combined with other creams and ointments in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is PUVA therapy when combined with other medicines taken by mouth in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Physical therapies	Devices	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

How effective is skin grafting in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Surgery		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is taking psoralen by mouth combined with exposure to natural sunlight (oral PUVAso) in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is the introduction of foreign bodies (such as intestinal worms) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Unclassified			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is UVA light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is UVA light therapy when combined with creams or ointments (e.g. khellin, lactic acid, steroid creams) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is UVA light therapy when combined with treatments taken by mouth (e.g. phenylalanine, khellin) in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

How effective is UVB light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is UVB light therapy when combined with creams or ointments (e.g. steroid creams) in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 4 Vitiligo Ranked 4; Patient rank 0, HP 13	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is UVB light therapy when combined with medicines taken by mouth in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo NCT01006421	Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective is UVB light therapy when combined with the needling technique in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How much do psychological interventions (such as counselling) help people with vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Psychological therapy			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 2 Vitiligo Ranked 2; Patient Rank 6, HP 6	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How safe is pseudocatalase cream combined with UVB light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Safety
How safe is PUVA therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Safety

How safe is skin grafting in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Safety
How safe is UVA light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Safety
How safe is UVB light therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Safety
Is pseudocatalase cream combined with brief exposure to UVB light as recommended, effective in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Physical therapies	Devices	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 10 Vitiligo Ranked 10; Patient rank 0; HP 0	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Is PUVA therapy more effective if used to treat vitiligo when it first appears, rather than waiting until the disease has spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Is UVB light therapy more effective in treating vitiligo when it first appears, rather than waiting until the disease has spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
What role might chemotherapy treatments play in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

What role might gene therapy play in the treatment of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Vaccines and biologicals			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 5 Vitiligo Ranked 5; Patient rank 2, Health P 4	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
What role might stem cell therapy play in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Surgery			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 12	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
When is the best time to consider depigmentation?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			depigmentation
Which treatment is more effective for vitiligo: calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) or light therapy?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) or steroid cream?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082393	Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) or steroid creams/ointments?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 7 Vitiligo Ranked 7; Patient rank 0, HP 2	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) or vitamin D analogues (e.g. calcipotriol)?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

Which treatment is more effective for vitiligo: laser or other light therapy?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: light therapy or calcineurin inhibitors (e.g. tacrolimus, pimecrolimus)?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 3 Vitiligo Ranked 3; Patient Rank 0, HP 10	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: melagenina or UV light?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: psoralen taken by mouth or psoralen cream/ointment?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: steroid cream or a different cream that suppresses the immune system?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatment is more effective for vitiligo: steroid creams/ointments or light therapy?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Physical therapies	Devices	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 8 Vitiligo Ranked 8; Patient rank 0, HP 10	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Which treatments are more effective for improving the quality of life of patients with vitiligo: psychological interventions or treatments to aid repigmentation?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life